YAU renal cancer spotlight: how should cost-effectiveness affect decision-making regarding adjuvant pembrolizumab for clear cell renal cell carcinoma?

被引：2
作者：
Erdem, Selcuk [1 ,2 ]
Marandino, Laura [2 ,3 ]
Roussel, Eduard [2 ,4 ]
Ciccarese, Chiara [2 ,5 ]
Amparore, Daniele [2 ,6 ]
Campi, Riccardo [2 ,7 ]
机构：
[1] Istanbul Univ, Div Urol Oncol, Dept Urol, Istanbul Fac Med, Istanbul, Turkiye
[2] Young Acad Urologists YAU Renal Canc Working Grp, European Assoc Urol EAU, Arnhem, Netherlands
[3] Royal Marsden NHS Fdn Trust, Skin & Renal Unit, London, England
[4] Univ Hosp Leuven, Dept Urol, Leuven, Belgium
[5] IRCCS A Gemelli Univ Polyclin Fdn, Dept Med & Surg Sci, Med Oncol Unit, Rome, Italy
[6] Univ Turin, San Luigi Gonzaga Hosp, Dept Urol, Turin, Italy
[7] Univ Florence, Dept Expt & Clin Med, Urol Robot Surg & Renal Transplantat Unit, Careggi Hosp, Florence, Italy
来源：
MINERVA UROLOGY AND NEPHROLOGY | 2024年 / 76卷 / 06期
关键词：
HIGH-RISK; SURGICAL RESECTION; PATIENT SELECTION; PHASE-III; NEPHRECTOMY; RECURRENCE; SURVIVAL; ORGANIZATION; INTERFERON;
D O I：
10.23736/S2724-6051.24.06268-2
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：797 / 801
页数：5
相关论文
共 24 条
[1]   Adjuvant 5-flurouracil, alpha-interferon and interleukin-2 versus observation in patients at high risk of recurrence after nephrectomy for renal cell carcinoma: Results of a Phase III randomised European Organisation for Research and Treatment of Cancer (Genito-Urinary Cancers Group)/National Cancer Research Institute trial [J].
Aitchison, M. ;
Bray, C. A. ;
Van Poppel, H. ;
Sylvester, R. ;
Graham, J. ;
Innes, C. ;
McMahon, L. ;
Vasey, P. A. .
EUROPEAN JOURNAL OF CANCER, 2014, 50 (01) :70-77
[2]   A protocol for performing extended lymph node dissection using primary tumor pathological features for patients treated with radical nephrectomy for clear cell renal cell carcinoma [J].
Blute, ML ;
Leibovich, BC ;
Cheville, JC ;
Lohse, CM ;
Zincke, H .
JOURNAL OF UROLOGY, 2004, 172 (02) :465-469
[3]   The World Health Organization 2022 Classification of renal tumors: key updates for urologists [J].
Calio, Anna ;
Amparore, Daniele ;
Roussel, Eduard ;
Bertolo, Riccardo ;
Erdem, Selquk ;
Marchioni, Michele ;
Pavan, Nicola ;
Campi, Riccardo .
MINERVA UROLOGY AND NEPHROLOGY, 2023, 75 (06) :766-769
[4]   Could a Risk-adapted Approach Support Shared Decision-making Regarding Eligibility for Adjuvant Pembrolizumab for Patients with Clear Cell Renal Cell Carcinoma at High Risk of Recurrence? A Multicentre Cohort Study [J].
Campi, Riccardo ;
Pecoraro, Alessio ;
Roussel, Eduard ;
Amparore, Daniele ;
Mari, Andrea ;
Montorsi, Francesco ;
Porpiglia, Francesco ;
Albersen, Maarten ;
Capitanio, Umberto ;
Minervini, Andrea ;
Serni, Sergio ;
Bertolo, Riccardo .
EUROPEAN UROLOGY ONCOLOGY, 2024, 7 (03) :323-327
[5]   Oncological safety of partial nephrectomy for pT3a renal cell carcinoma: reading between the lines [J].
Campi, Riccardo ;
Diana, Pietro ;
Muselaers, Stijn ;
Erdem, Selcuk ;
Marchioni, Michele ;
Ingels, Alexandre ;
Kara, Onder ;
Carbonara, Umberto ;
Pavan, Nicola ;
Marandino, Laura ;
Roussel, Eduard ;
Bertolo, Riccardo .
MINERVA UROLOGY AND NEPHROLOGY, 2022, 74 (04) :488-491
[6]   Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma [J].
Choueiri, T. K. ;
Tomczak, P. ;
Park, S. H. ;
Venugopal, B. ;
Ferguson, T. ;
Symeonides, S. N. ;
Hajek, J. ;
Chang, Y-H ;
Lee, J-L ;
Sarwar, N. ;
Haas, N. B. ;
Gurney, H. ;
Sawrycki, P. ;
Mahave, M. ;
Gross-Goupil, M. ;
Zhang, T. ;
Burke, J. M. ;
Doshi, G. ;
Melichar, B. ;
Kopyltsov, E. ;
Alva, A. ;
Oudard, S. ;
Topart, D. ;
Hammers, H. ;
Kitamura, H. ;
McDermott, D. F. ;
Silva, A. ;
Winquist, E. ;
Cornell, J. ;
Elfiky, A. ;
Burgents, J. E. ;
Perini, R. F. ;
Powles, T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2024, 390 (15) :1359-1371
[7]   Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma [J].
Choueiri, T. K. ;
Tomczak, P. ;
Park, S. H. ;
Venugopal, B. ;
Ferguson, T. ;
Chang, Y. -H. ;
Hajek, J. ;
Symeonides, S. N. ;
Lee, J. L. ;
Sarwar, N. ;
Thiery-Vuillemin, A. ;
Gross-Goupil, M. ;
Mahave, M. ;
Haas, N. B. ;
Sawrycki, P. ;
Gurney, H. ;
Chevreau, C. ;
Melichar, B. ;
Kopyltsov, E. ;
Alva, A. ;
Burke, J. M. ;
Doshi, G. ;
Topart, D. ;
Oudard, S. ;
Hammers, H. ;
Kitamura, H. ;
Bedke, J. ;
Perini, R. F. ;
Zhang, P. ;
Imai, K. ;
Willemann-Rogerio, J. ;
Quinn, D. I. ;
Powles, T. .
NEW ENGLAND JOURNAL OF MEDICINE, 2021, 385 (08) :683-694
[8]   Adjuvant pembrolizumab prolongs overall survival in renal cell carcinoma at high-risk of recurrence after nephrectomy. Can we do better than this? [J].
Ciccarese, Chiara ;
Mollica, Veronica ;
Marandino, Laura ;
Palumbo, Carlotta ;
Campi, Riccardo ;
Amparore, Daniele .
MINERVA UROLOGY AND NEPHROLOGY, 2024, 76 (05) :540-544
[9]   Predicting Disease Recurrence, Early Progression, and Overall Survival Following Surgical Resection for High-risk Localized and Locally Advanced Renal Cell Carcinoma [J].
Correa, Andres F. ;
Jegede, Opeyemi A. ;
Haas, Naomi B. ;
Flaherty, Keith T. ;
Pins, Michael R. ;
Adeniran, Adebowale ;
Messing, Edward M. ;
Manola, Judith ;
Wood, Christopher G. ;
Kane, Christopher J. ;
Jewett, Michael A. S. ;
Dutcher, Janice P. ;
DiPaola, Robert S. ;
Carducci, Michael A. ;
Uzzo, Robert G. .
EUROPEAN UROLOGY, 2021, 80 (01) :20-31
[10]   Can a Durable Disease-Free Survival be Achieved With Surgical Resection in Patients With Pathological Node Positive Renal Cell Carcinoma? [J].
Delacroix, Scott E., Jr. ;
Chapin, Brian F. ;
Chen, Jaclyn J. ;
Nogueras-Gonzalez, Graciela M. ;
Tamboli, Pheroze ;
Matin, Surena F. ;
Wood, Christopher G. .
JOURNAL OF UROLOGY, 2011, 186 (04) :1236-1241
123